New drug combo shows promise for Hard-to-Treat prostate cancer
NCT ID NCT05960578
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining golimumab (an anti-inflammatory drug) with apalutamide (a hormone blocker) can help men with castration-resistant prostate cancer that has spread. The study enrolled 8 participants and measures PSA reduction and tumor shrinkage. The goal is to find a more effective treatment for this advanced stage of prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Golimumab and apalutamide
- What this could lead to
- If successful, this combination could offer a new treatment option for men with castration-resistant prostate cancer, potentially slowing tumor growth and lowering PSA levels.
- What could go wrong
- This is a very small early-phase trial with only 8 participants, so results may not apply to all patients. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can surgery boost control of spread prostate cancer?
- Can a better scan sharpen radiation for prostate cancer?
- Hormone therapy showdown: can an oral pill beat the shot for prostate cancer patients?
- Can tracking tumor movement during radiation make treatment more precise?
- Mapping radiation dose in real time: a smarter way to treat prostate cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?